GSK237701A

GSK237701A is a synthetic small molecule belonging to the benzimidazole class. It was developed as an experimental compound and is known for its activity as a kinase inhibitor, specifically targeting serine/threonine-protein kinases such as Polo-like kinase 1 (PLK1) and Polo-like kinase 3 (PLK3). These kinases are involved in cell cycle regulation and mitosis. The compound has been investigated primarily as a research tool for studying PLK inhibition and has potential applications in oncology due to the role of PLKs in cancer cell proliferation. There is no evidence of clinical development or approval for therapeutic use[2][4][5].

Other names

5-[5,6-Bis(Methyloxy)-1H-Benzimidazol-1-Yl]-3-{[1-(2-Chlorophenyl)ethyl]oxy}-2-Thiophenecarboxamide3-[(1R)-1-(2-chlorophenyl)ethoxy]-5-(5,6-dimethoxy-1H-benzimidazol-1-yl)-2-thiophenecarboxamide862813-28-3